382150 — OncoCross Co Cashflow Statement
0.000.00%
- KR₩144bn
- KR₩123bn
- KR₩1bn
Annual cashflow statement for OncoCross Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -10,204 | -4,214 | -6,483 |
| Depreciation | |||
| Amortisation | |||
| Non-Cash Items | 755 | -702 | 189 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 881 | -428 | 364 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Taxes Payable | |||
| Change in Other Liabilities | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -8,200 | -4,906 | -5,524 |
| Capital Expenditures | -341 | -24.7 | -174 |
| Purchase of Fixed Assets | |||
| Purchase / Acquisition of Intangibles | |||
| Other Investing Cash Flow Items | 8,613 | -918 | -469 |
| Sale of Fixed Assets | |||
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | 8,272 | -943 | -642 |
| Financing Cash Flow Items | -19.9 | -1.08 | -651 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 1,422 | 14,297 | 9,857 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 1,541 | 8,450 | 3,700 |